Further information

National Breast Screen Incident

Following an investigation started in January 2018, Public Health England and NHS England identified that in some instances women were not being invited for their final breast screen between their 68th and 71st birthday.

Data has been analysed back to 2009 and an estimated 206,000 women on a GP register in England , now aged 70 – 79 years, will receive a letter. Those aged up to 72 will be sent a catch up screening invitation. Women aged 72 and above will be offered the opportunity for a screen. Routine breast screening will be unaffected and most women in these age groups will still have received their final screen.
If you think you may be affected:
§ call the breast screening helpline number 0800 169 2692
§ go the NHS Choices website for more information
§ you should receive a letter by the end of May

Please see attached link for booklet about the NHS Breast Screening Programme.

NHS Breast Screening Programme booklet



Please see link below to read about the benefits that drinking more water has for your overall health!

The Benefits of Drinking More Water Infographic_


Last year 21.6 million prescription items were dispensed for patients covered by the Birmingham and Solihull Clinical Commissioning Group (CCG) at a cost of £185 million. The Policy for items which should not routinely be prescribed in primary care will help us to make sure that we make wise use of NHS prescribing resources for the benefit of everyone.
This policy sets out the CCG’s position on 18 products previously available on NHS prescription in Birmingham and Solihull, each of which falls into one of the following categories:
·         Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness, or there are significant safety concerns
·         Products which are clinically effective but where more cost-effective options are available, including products which have been subject to excessive price inflation
·         Products which are clinically effective, but due to the nature of the product, are deemed low priority for NHS funding.
It is based on the NHS England/NHS Clinical Commissioners Items which should not routinely be prescribed in primary care: Guidance for CCGs, and covers the following products:
·         Co-proxamol
·         Dosulepin
·         Glucosamine and chondroitin
·         Herbal treatments
·         Homoeopathy
·         Immediate release fentanyl (not fentanyl patches)
·         Lidocaine plasters
·         Liothyronine
·         Lutein and antioxidants
·         Once daily Tadalafil
·         Omega-3 fatty acid compounds
·         Perindopril arginine
·         Prolonged release doxazosin
·         Rubifacients (excluding topical non-steroidal anti-inflammatory drugs – NSAIDs)
·         Targinact – Oxycodone and naloxone combination product
·         Tramacet – paracetamol and tramadol combination product
·         Trimipramine
·         Vaccines administered exclusively for the purposes of travel
The policy sets out more information regarding the approach to each of the products and you can also find out more by reading the patient information above.
GP practices will no longer start new prescriptions for these products and, over the coming months, will be reviewing patients already receiving prescriptions. As always, they will use their clinical skills and judgement in caring for individual patients, whilst making best use of NHS resources for the benefit of all patients. Practices will be contacting patients in due course, and there is no need to make an appointment before this unless you have concerns over your condition.
CCGs have limited budgets which are used to commission healthcare that meets the reasonable requirements of their patients. This policy helps us to prioritise resources using the best evidence about what is clinically effective, to provide the greatest proven health gain for the whole of the CCG’s population. Our intention is to ensure access to NHS funding is equal and fair, whilst considering the needs of the overall population and evidence of clinical and cost effectiveness.